Cleerly to Debut Customizable Full Text Reports and Present New AI-QCT Research at SCCT2026

New Full Text Report Configurability and Six Scientific Presentations at the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography

July 7, 2026 (DENVER, CO) - Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT2026). The conference will take place July 9-12, 2026, at the Gaylord Pacific Resort in Chula Vista, California. SCCT2026 brings together clinicians and researchers from around the world to advance the science and practice of cardiovascular computed tomography.

Cleerly will debut new customization capabilities for its Full Text Report, giving provider teams the ability to configure the structured narrative generated by itsartificial intelligence-enabled quantitative computed tomography (AI-QCT) platform. In addition, Cleerly will present findings from six scientific abstracts spanning plaque quantification, risk stratification, and cardiovascular outcomes, including five studies that draw on data from the CONFIRM2 Registry. CONFIRM2 is a multicenter, international, observational cohort targeting 30,000 patients, with more than 10,750 participants currently enrolled, that aims to perform comprehensive quantification of computed tomography (CT) angiography findings and relate them to clinical variables and cardiovascular outcomes.

New Full Text Report Customization

The Full Text Report is a structured narrative populated with Cleerly LABS plaque analysis and Cleerly ISCHEMIA and generated using a site-configurable report template. It provides a clinician-ready summary of the coronary computed tomography angiography (CCTA) analysis across five key domains:

• Atherosclerosis: Plaque volumes, including total plaque volume (TPV), calcified plaque (CP), noncalcified plaque (NCP), and low-density noncalcified plaque (LD-NCP), with percent atheroma volume (PAV), reported at both the patient and territory levels.
• Stenosis: Per-segment diameter stenosis grouped by category (Severe, Moderate, Mild, Minimal, and Zero), with segment counts and lists.
• Ischemia and CAD-RADS: Cleerly ISCHEMIA status with implicated vessels, plus the overall Coronary Artery Disease Reporting and Data System (CAD-RADS) score.
• Anatomy: Coronary dominance, stents, chronic total occlusions (CTOs), anomalies, bifurcated lesions, and exclusions with documented reasons.
• Site-configurable report template: The Full Text Report can be generated using site-configurable report templates to support individual clinical workflows. Report templates allow customization of sections, field order, headings, and static text. Blank sections are omitted automatically, and clinically appropriate phrasing is generated based on the analysis findings.

"The Full Text Report brings together all the information a clinician needs to understand a patient's full coronary profile, including plaque burden, stenosis severity, ischemia status, and anatomy. By making that output configurable to each practice's workflow, the depth of AI-QCT analysis can translate easily into clinical action. We look forward to connecting with the SCCT community. Stop by one of our sessions or come see us at Booth #301," said James K. Min, MD, founder and CEO of Cleerly.

Conference Schedule

Thursday, July 9

• 1:00 PM | AI and Innovations Symposium | Chula Vista 1 (Separate registration required)

Friday, July 10

• 7:00-7:50 AM | Cleerly Breakfast Symposium: Plaque Evolution: How AI & Serial Scanning Can Change the Game | Chula Vista 6
• • Speakers:
  • • James K. Min, MD, Founder & CEO, Cleerly
    • Udo Hoffmann, MD, MPH, Chief Medical, Scientific and AI Officer, Cleerly
    • Neerav Sheth, MD, MBA, Interventional Cardiologist, Cardiology Consultants of Philadelphia
    • Brittany Weber, MD, PhD, Director, Cardio-Rheumatology/Cardio-Dermatology Program, UT Southwestern
• 9:30-10:15 AM | Poster Session 2, #417: Beyond Risk Factors: Additive Role of Noncalcified Plaque Volume in Risk Stratification for Cardiovascular Events
• 9:30-10:15 AM | Poster Session 13, #526: Age- and Sex-Specific Plaque Percentiles and Absolute Risk Zones from AI-QCT: Insights from CONFIRM2
• 2:55-3:15 PM | Product Showcase: Turning Insights into Action: The Purpose-Built Evolution of Cleerly | Product Showcase Theater
• 3:30-5:00 PM | AI Plaque Wars! | Chula Vista 6
• 5:34-5:42 PM | Novel Technologies: Why the Next Five Years will be Transformational: New Programs, New Science | Chula Vista 4

Saturday, July 11

• 10:55-11:40 AM | Poster Session 20, #599:Impact of Statin and Aspirin on Plaque Composition: Data from the CONFIRM2 Registry
• 10:55-11:40 AM | Poster Session 20, #601: Association of Cardiac Symptoms with Quantitative Coronary Atherosclerosis, Stenosis, and Ischemia: Results from the CONFIRM2 Registry
• 10:55-11:40 AM | Poster Session 20, #612: AI-Derived Plaque Quantification and Risk Stratification in Asymptomatic Individuals: A Sub-analysis of the CONFIRM2 Registry
• 10:55-11:40 AM | Poster Session 20, #628: Discordance between PREVENT Clinical Risk Score, Coronary Artery Calcium, and Quantitative Non-Calcified Plaque in Asymptomatic South Asian Adults: Insights from the SACTA Registry
• 1:40-2:10 PM | Meet and Greet with Cleerly Leadership | Booth #301
  
  

Cleerly at SCCT2026

Join Cleerly on Friday, July 10, from 7:00-7:50 AM for Cleerly's Breakfast Symposium at Chula Vista 6 and Saturday, July 11, from 1:40-2:10 PM at Booth #301 for a meet-and-greet with Cleerly's leadership team. Stop by Booth #301 throughout the conference for live demonstrations of Cleerly's technology, clinical evidence, and discussions with our expert team. A barista will be on-site Friday and Saturday throughout exhibit hall hours.

To view the full schedule of Cleerly presentations or to schedule a meeting with Cleerly leadership, visit cleerlyhealth.com/scct-2026.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly's approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.